National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Roxadustat (Evrenzo™). HTA ID: 21037

Roxadustat (Evrenzo™) is indicated for the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease.

 

NCPE Assessment Process Complete
Rapid review commissioned 01/09/2021
Rapid review completed 06/10/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that roxadustat not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.